EGFR and neoplasm: A panel of 9 BRAF mutant metastatic CM cell cultures, which were made resistant to the PLX4032 BRAFi, was used as a model to evaluate: i) the expression of RTK and their ligands in CM cells acquiring BRAFi resistance; ii) the effect of EGFR targeting by small molecule inhibitors, mAbs, and genomic editing approaches on BRAFi sensitivity; and iii) the anti-tumor efficacy of EGFR targeting mAbs through ADCC.